Cardiologists' Perspectives on BiDil and the Use of Race in Drug Prescribing.
Cardiologists' Perspectives on BiDil and the Use of Race in Drug Prescribing.
复制标题
心脏病学家对 BiDil 的看法以及在药物处方中使用种族。
DOI：
10.1007/s40615-021-01153-x
复制
发表时间：
2022
影响因子：
3.9
通讯作者：
Royal,CharmaineDM
中科院分区：
文献类型：
--
作者：
Callier,ShawneequaL;PayneJr,PerryW;Akinniyi,Deborah;McPartland,Kaitlyn;Richardson,TerryL;Rothstein,MarkA;Royal,CharmaineDM
ObjectivesWe explored cardiologists’ attitudes and prescribing patterns specific to the use of generic isosorbide dinitrate and hydralazine hydrochloride, and the fixed-dose patented drug, BiDil.BackgroundSince the Food and Drug Administration approved BiDil in 2005 with an indication for self-identified black patients, disagreement about the appropriateness of race-based drugs has intensified and led to calls for providers and researchers to abandon race-based delimitations. This paper reports empirical evidence of cardiologists’ views on BiDil’s race-based indication and their ongoing inertia with respect to the debate about BiDil.MethodsWe conducted a 2010 cross-sectional online survey of members of the Association of Black Cardiologists.ResultsFifty-nine cardiologists responded to the survey. Most participants (62.7%) prescribed BiDil to their patients. More than 40% of respondents did not prescribe BiDil to any non-African Americans. When considering whether to prescribe BiDil, a patient’s race determined by physician assessment was the third most important factor considered by participants. The majority of participants (72.7%) selected symptoms as the most important factor. Most participants (59.2%) perceived race as defining biologically distinct individuals. Respondents prescribed BiDil more often to African American patients than non-African American patients. However, they prescribed the generic components that makeup BiDil to African Americans and non-African American patients similarly.ConclusionsThe survey provides useful findings that, when viewed within the context of ongoing debates about race-based medicine, show little progress toward appropriately utilizing BiDil to maximize health outcomes, yet, might inform the development of practical and effective guidelines concerning the use of race in medicine.
